Mechanisms of action of etidronate and other bisphosphonates

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 4, 1998, Pages 233-243

  Ebetino, Frank H ^a   Francis, Marion D ^a   Rogers, Michael J ^b   Russell, R Graham G ^c  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ION; CALCIUM PHOSPHATE; ETIDRONIC ACID; MEVALONIC ACID; NITROGEN;

ADSORPTION; BONE CELL; BONE METABOLISM; CALCIUM CELL LEVEL; CHEMICAL STRUCTURE; DRUG BINDING; DRUG POTENCY; DRUG SAFETY; EXTRACELLULAR CALCIUM; GASTROINTESTINAL SYMPTOM; HETEROTOPIC OSSIFICATION; OSTEOCLAST; OSTEOPOROSIS; PAGET BONE DISEASE; PRENYLATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0031832457     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Amin D, Cornell SA, Gustafson SK. et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992; 33: 1657-1663.
2. Amin D, Cornell SA, Perrone MH, Bilder GE. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res 1996; 46: 759-762.
3. Auriola S, Frith J, Rogers MJ, Koivuniemi A, Mönkkönen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chrom B 1997; 704: 187-195.
4. Baron R. Molecular mechanisms of bone resorption by the osteoclast. Anat Rec 1989; 224: 317-324.
5. Baron R, Neff L, Louvard D, Courtoy PJ. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 1985; 101: 2210-2222.
6. Benedict JJ. The physical chemistry of the diphosphonates - its relationship to their medical activity. In: Donath A, Courvoiser B, eds. Symposium CEMO. IV. Diphosphonates and bone. Geneva: Editions Medicine et Hygiène, 1982: 1-19.
7. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989; 245: 855-857.
8. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Wil Thesing C, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986; 1: 27-39.
9. Boonekamp PM, Löwik LJA, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Bijvoet OLM. Enhancement of the inhibitory actions of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner 1987; 2: 29-42.
10. Carano A, Teitelbaum SA, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro, J Clin Invest 1990; 85: 456-461.
11. Datta HK, MacIntyre I, Zaidi M. Intracellular calcium in the control of osteoclast function. Voltage-insensitivity and lack of effects of nifedipine, BAYK8644 and diltiazem. Biochem Biophys Res Commun 1990; 167: 807.
12. +-ATPase. J Bone Miner Res 1996; 11: 1498-1507.
13. Donahue HJ. Signal transduction mechanisms in osteoclasts. In: Rifkin BR, Gay CV, eds. Biology and physiology of the osteoclast. London: CRC Press, 1992: 207-222.
14. D'Souza SM, Orcutt CM, Ibbotson KJ. Inhibitory effects of bisphosphonates on rat osteoblast-like cells: correlation with anti-resorptive potency. J Bone Miner Res 1990; 5: S90.